Welcome to AMYPAD!
We were a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging. Our aims were:
- to improve the diagnostic work-up of people suspected to have Alzheimer’s disease and their management
- to understand the natural history of the disease in a pre-symptomatic stage
- to select people for treatment trials aiming at preventing Alzheimer’s disease
💡 You can now make a formal request to access our data!
|
|
|
Please note that the AMYPAD PNHS study is transitioning into the Euro-PAD community, and its data will be migrated over the coming months.
Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
The AMYPAD raw dataset is now available for data access request
23 Apr 2025
We are pleased to announce that the Amyloid Imaging to Pr...
AMYPAD at #ADPD2025
02 Apr 2025
Attendees of #ADPD2025 were able to receive an array of informative AMYPAD, EPAD and Euro-PAD oral talks....
AMYPAD at #ECCN2025
25 Mar 2025
An AMYPAD satellite symposium sponsored by Life Molecular Imaging took place at ECCN2025....
"We would hope that the direct results of the project are useful about our thinking of when amyloid deposition starts and when it's clinically relevant. But what is even more important is that the consortium that we formed, started collaborating on things that go well beyond the initial goals of AMYPAD. And actually, we should further integrate AMYPAD, EPAD and all the European cohorts that are now collaborating and joining forces in analysis of PET/MRI scans, imaging, biomarker but also genetic data. It is something of great value and will contribute to the future of all samples, definitely in Europe and hopefully also globally. ” Frederik Barkhof
AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.
